| Circulating tumor DNA | ctDNA |
| Combined positive score | CPS |
| Cutaneous squamous cell carcinoma | cSCC |
| Circulating tumor DNA | ctDNA |
| Cross-validation score | CV score |
| DNA damage repair | DDR |
| Eastern Cooperative Oncology group | ECOG |
| Immune-related Response Evaluation Criteria in Solid Tumors | iRECIST |
| Leave-one-out cross-validation | LOO-CV |
| Multivariate analysis of variance | MANOVA |
| Microsatellite instability | MSI |
| Mismatch repair | MMR |
| National Comprehensive Cancer Network | NCCN |
| Next generation sequencing | NGS |
| Overall survival | OS |
| Principal component analysis | PCA |
| Programmed cell death protein 1 | PD-1 |
| Programmed death-ligand 1 | PD-L1 |
| Progression-free survival | PFS |
| Radiation therapy | RT |
| Tumor tissue DNA | tDNA |
| Tumor microenvironment | TME |
| Tumor mutational burden | TMB |
| Tumor proportion score | TPS |
| Support vector classifier | SVC |
| SWItch/Sucrose Non-Fermentable | SWI/SNF |